OncoMatch/Clinical Trials/NCT06811233
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Is NCT06811233 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including DMSA and Ca-EDTA for acute myeloid leukemia (aml).
Treatment: DMSA · Ca-EDTA · Magnesium Sulfate · Multivitamin — The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: bcl2 inhibitor (venetoclax)
Lab requirements
Kidney function
Serum creatinine ≤ 2.0 mg/dL
Liver function
Total Bilirubin ≤ 2.0 x ULN unless the patient has Gilbert's; AST (SGOT) and/or ALT (SGPT) ≤ 2.0 x ULN
Laboratory test results within these ranges (unless due to leukemia or other hematologic malignancy): Serum creatinine ≤ 2.0 mg/dL; Total Bilirubin ≤ 2.0 x ULN unless the patient has Gilbert's; AST (SGOT) and/or ALT (SGPT) ≤ 2.0 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify